RVL Pharmaceuticals, Inc.
10
0
0
8
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 5/100
10.0%
1 terminated/withdrawn out of 10 trials
88.9%
+2.4% vs industry average
90%
9 trials in Phase 3/4
75%
6 of 8 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (10)
A Study to Investigate Arbaclofen ER Tablets for the Treatment of Spasticity in Patients With Multiple Sclerosis
Role: lead
A Study to Evaluate the Long-term Safety of Arbaclofen Extended-Release Tablets for Patients With Spasticity Due to MS
Role: lead
A Study to Investigate the Safety and Effectiveness of Arbaclofen Extended-Release Tablets for Patients With MS
Role: lead
To Assess Effects of Arbaclofen ER Tablets Compared With Placebo on Sperm Parameters in Male Subjects With MS
Role: lead
Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis
Role: lead
One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity
Role: lead
Safety and Efficacy Study of RVL-1201 in Acquired Blepharoptosis
Role: lead
Study of the Safety and Efficacy of RVL-1201 in the Treatment of Acquired Blepharoptosis
Role: lead
Study of Safety of RVL-1201 in Treatment of Blepharoptosis
Role: lead
Study of Safety and Efficacy of RVL-1201 in the Treatment of Blepharoptosis
Role: lead
All 10 trials loaded